NRX Pharmaceuticals
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $1,068 | $983 | $242 | $0 |
Gross Profit | 272 | 475 | 104 | |
EBITDA | -4,583 | -4,494 | -4,077 | -17,581 |
EBIT | -4,748 | -4,594 | -4,118 | -3,730 |
Net Income | -1,430 | 360 | -5,890 | -17,581 |
Net Change In Cash | 1,068 | 983 | 242 | 0 |
Free Cash Flow | -4,295 | -3,713 | -2,891 | -4,028 |
Cash | 6,713 | 7,797 | 7,184 | 2,910 |
Basic Shares | 32,325 | 31,734 | 22,231 | 17,934 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $1,225 | $0 | $0 | $0 |
Gross Profit | 720 | -5 | -5 | -4 |
EBITDA | -27,808 | -24,042 | -30,025 | -39,750 |
EBIT | -27,951 | -24,047 | -30,030 | -39,754 |
Net Income | -28,622 | -25,126 | -30,150 | -39,754 |
Net Change In Cash | 1,225 | 0 | 0 | 0 |
Free Cash Flow | -14,112 | -10,637 | -21,660 | -39,765 |
Cash | 7,797 | 1,443 | 4,595 | 20,054 |
Basic Shares | 21,401 | 10,517 | 7,576 | 65,767 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.04 |
2025-12-31 | $0.18 |
2025-09-30 | -$0.27 |
2025-06-30 | -$0.98 |